News Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:39:13 09/02/2026 GMT			5-day change	1st Jan Change
2.380 ^AUD	+6.73%		-4.05%	-12.87%

02-06	ASX Biggest Losers	MT
01-29	Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%	MT

02-06	ASX Biggest Losers	MT
01-29	Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%	MT
01-28	Ryoncil® Net Revenues Increase for the Quarter to US$30M	AQ
01-27	Mesoblast Limited Announces Update on Ryoncil (remestemcel-L-rknd) for Pediatric SR-aGvHD and Plans for Adult Trials	CI
01-27	Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting	MT
01-26	Mesoblast says Ryoncil shows 84% survival rate in children with Sr-Agvhd	RE
01-26	Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment	AQ
01-21	Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of a Biologics License Application for its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain	CI
01-19	MESOBLAST LIMITED - FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY	AQ
01-19	Mesoblast Limited Provides Feedback Received from the U.S. Food & Drug Administration on Potential Filing of A Biologics License Application for Its Allogeneic Cell Therapy Product Rexlemestrocel-L in Patients with Chronic Low Back Pain	CI
01-19	Mesoblast Says FDA Acknowledges Potential Efficacy of Cell Therapy Product	MT
01-19	Mesoblast says FDA acknowledges effects on pain intensity favor rexlemestrocel-L	RE
01-19	FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy	AQ
01-16	ASX Biggest Losers	MT
01-14	ASX Biggest Losers	MT
01-14	Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies	MT
01-13	ASX Biggest Losers	MT
01-09	Mesoblast Shares Rise After Ryoncil Sales Jump in Q4	MT
01-09	Mesoblast Says US Revenue From Sale of Cell Therapy Rises Quarter-on-Quarter in December 2025 Quarter; Shares Reach Five-Year Peak	MT
01-09	Mesoblast says Ryoncil sales for quarter increase 60% to $35.1M	RE
01-09	ASX Biggest Gainers	MT
01-09	ASX Most Active Stocks	MT
01-08	Mesoblast Says US Revenue From Sale of Cell Therapy Rises Quarter-on-Quarter in December 2025 Quarter	MT
01-08	Ryoncil® Sales Increase 60% in December Quarter to US$35.1M	AQ
01-08	ASX Biggest Gainers	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Filters